Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity

Life Sciences

Volumn 76, Issue 16, 2005, Pages 1825-1834

  Asna, N ^a,b   Lewy, H ^a   Ashkenazi, I E ^a   Deutsch, V ^b   Peretz, H ^b   Inbar, M ^b   Ron, I G ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Amifostine; Chronotherapy; Cisplatin; Myelotoxicity; Nephrotoxicity

Indexed keywords

AMIFOSTINE; CISPLATIN; CREATININE; ETHIOL; HEMOGLOBIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BONE MARROW TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; LIGHT DARK CYCLE; MALE; MOUSE; MOUSE STRAIN; NEPHROTOXICITY; NONHUMAN; PROTECTION; THROMBOCYTE COUNT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

EID: 13544276555     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.09.028     Document Type: Article

References (31)

1. H. Anderson, J. Wagstaff, D. Crowther, R. Swindell, M.J. Lind, J. McGregor, and M.S. Timms Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer Eurpean Journal of Cancer Clinical Oncology 24 9 1988 1471 1479
2. M. Boisdron-Celle, A. Lebouil, P. Allain, and E. Gamelin Pharmacokinetic properties of platinium derivatives Bulletin du Cancer S14-9 2001
3. N.A. Boughattas, F. Levi, C. Fournier, B. Hecquet, G. Lemaigre, A. Roulon, G. Mathe, and A. Reinberg Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice Journal of Pharmacology and Experimental Therapeutics 255 1990 672 679
4. D.C. Bruce Miscellaneous chemotherapeutic agents V.T. DeVitta S. Hellman S.A. Rosenberg Cancer principles and practice of oncology 2001 Lippincott Williams and Wilkins Philadelphia 452 459
5. R.L. Capizzi, B.J. Scheffler, and P.S. Schein Amifostine mediated protection of normal bone marrow from cytotoxic chemotherapy Cancer 72 1993 3495 3501
6. R.L. Capizzi Amifostine: The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies Seminars in Oncology 23 1996 2 17
7. RL. Capizzy, and W. Oster Chemoprotective and radioprotective effects of amifostine: an update of clinical trials International Journal of Hematology 72 2000 425 435
8. M.P. Decatris, S. Sundar, and K.J. O'Byrne Platinum-based chemotherapy in metastatic breast cancer: current status Cancer Treatment Review 30 1 2004 53 81
9. A.M. Guarino, D.S. Miller, S.T. Arnold, J.B. Pritchard, R.D. Davis, M.A. Urbanek, T.J. Miller, and C.L. Litterst Platinate toxicity: past, present and prospects Cancer Treatment Reports 63 1979 1475 1483
10. E. Halberg, F. Halberg, and K.J. Venner Twenty-four hour synchronized chronotolerance of cis-diamminedichloroplatinum (II) by rats on 8-h and 12-h photofraction gauged by acrophase and paraphase of rectal temperature A. Reinberg F. Halberg Chronopharmacology 1979 Pergamon Press New York 377
11. W.J. Hrushesky, F.A. Levi, F. Halberg, and B.J. Kennedy Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats Cancer Research 42 1982 945 949
12. W.J.M. Hrushesky, R.F. Borch, and F. Levi Circadian time dependence of cisplatin urinary kinetics Clinical Pharmacology and Therapeutics 32 1982 330 339
13. G. Kemp, P. Rose, J. Lurain, M. Berman, A. Manetta, B. Roullet, H. Homesley, D. Belpomme, and J. Glick Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer Journal of Clinical Oncology 14 7 1996 2101 2112
14. R.A. Lafayette, R.D. Perrone, and A.S. Levey Laboratory evaluation of renal function R.W. Schrier C.W. Gottschalk sixth ed. Diseases of the kidney vol. 1 1997 Little Brown and Company, New York 307 354
15. F. Levi, W.J.M. Hrushesky, C. Blomquist, D. Lakatua, E. Haus, F. Halberg, and B.J. Kennedy Reduction of cis-diamminedichloroplatinum toxicity in rats by optimal circadian drug timing Cancer Research 42 1982 950 955
16. F. Levi, W.J.M. Hrushesky, F. Halberg, T.R. Langevin, E. Haus, and B.J. Kennedy Lethal nephrotoxicity and hematologic toxicity of cis- diamminedichloroplatinum ameliorated by optimal circadian timing and hydration European Journal of Cancer Clinical Oncology 18 5 1982 471 477
17. F. Levi Chronopharmacology of anti cancer agents P.H. Redfern B. Lemmer Physiology and pharmacology of biological rhythms 1997 Springer-Verlag Heidelberg 299 333
18. C.E. Myers, W.P. McGuire, R.H. Liss, I. Ifrim, K. Grotzinger, and R.C. Young Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response Science 197 1977 165 167
19. L. Peleg, I.E. Ashkenazi, R. Carlebach, and S. Chaitchik Time dependent toxicity of drugs used in cancer chemotherapy: separate and combined administration International Journal of Cancer 44 1989 273 275
20. B.D. Rose Renal circulation and glomerular filtration rate B.D. Rose Clinical physiology of acid Base and electrolyte disorders fourth ed. 1994 McGROW- Hill Interantional ed New York 20 65
21. V. Santini Amifostine: chemotherapeutic and radiotherapeutic protective effects Expert Opinion on Pharmacotherapy 2 3 2001 479 489
22. A. Shakil, N. Hirabayashi, and T. Toge Circadian variation of 5-fluorouracil and cisplatinum toxicity in mice Hiroshima Journal of Medical Science 42 1993 147 154
23. J.H. Schiller High dose cisplatin and vinblastine plus amifostine for metastatic non small cell lung cancer Seminars in Oncology 23 1996 78 82
24. J. Stark Interpretation of BUN and serum creatinine. An interactive exercise Critical care nursing clinics of North America 10 1998 491 496
25. D.F. Swaab, E.J.W. VanSomeren, J.N. Zhou, and M.A. Hofman Biological rhythms in the human life cycle and their relationship to functional changes in the suprachiasmatic nucleus Progress in Brain Research 111 1996 349 368
26. H. To, A. Kikuchi, S.S.K. Tsuruoka, A. Fujimura, S. Higuchi, F. Kayama, K. Hara, K. Matsuno, and E. Kobayashi Time-dependent Nephrotoxicity associated with daily adminitration of cisplatin in mice Journal of Pharmaceutic Pharmacology 52 2000 1499 1504
27. M. Treskes, L.G. Nijtmans, A.M. Fichtinger-Schepman, and W.J. van der Vijgh Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithiocarbamate Biochemistry and Pharmacology 43 1992 1013 1019
28. M. Treskes, and W.J.F. van der Vijgh WR-2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: A molecular approach Cancer Chemotherapy and Pharmacology 33 1993 93 106
29. C.L. van der Wilt, J.A. van Laar, F. Gyergyay, K. Smid, and G.J. Peters Biochemical modification of the toxicity and the anti-tumor effect of 5-fluorouracil and cisplatinum by WR-2721 in mice European Journal of Cancer 28 1992 2017 2024
30. J.A. van Laar, C.L. van der Wilt, M. Treskes, W.J. van der Vijgh, and G.J. Peters Effect of WR-2721 on the toxicity and anti-tumor activity of the combination of carboplatin and 5-fluorouracil Cancer Chemotherapeutics and Pharmacology 31 1992 97 102
31. P.A. Wood, and W.J.M. Hrushesky Circadian timing of cancer chemotherapy M.C. Perry The chemotherapy source book second ed. 1996 Lippincott Williams and Wilkins Baltimore 177 202